

Table 1. Factors potentially correlated with seroreversion at 12 months of age

Variable	N	Seroreversion at 12 months of age		Crude OR (95%CI)	P	Adjusted OR (95%CI)	P**
		Seroreversion N (%)	No seroreversion N (%)				
Maternal age (years); median (IQR)		28 (23-32)	29 (25-33)	1.0 (0.99-1.00)	0.595		
< 20	55	38 (69.1)	17 (30.9)	1			
20 – <35	559	338 (60.5)	221 (39.5)	0.68 (0.38-1.24)	0.212	0.63(0.34-1.16)	0.137
≥ 35	112	56 (50.0)	56 (50.0)	0.45 (0.23-0.88)	0.021*	0.49(0.25-1.00)	0.051
ART antepartum	707	418 (59.1)	289 (40.9)				
No ART	83	55 (66.3)	28 (33.7)	1			
AZT	221	139 (62.9)	82 (37.1)	0.86 (0.51-1.47)	0.586		
AZT+3TC or d4T+3TC	82	52 (63.4)	30 (36.6)	0.88 (0.47-1.67)	0.701		
NNRTI –based ART [†]	150	95 (63.3)	55 (36.7)	0.88 (0.50-1.54)	0.655		
PI-based ART [‡]	171	77 (45.0)	94 (55.0)	0.42 (0.24-0.72)	0.002*	0.65(0.43-0.97)	0.033*
Duration of ART before delivery (months); median (IQR)		233(1.15-4.14)	265(1.40-5.28)	0.99 (0.99-1.00)	0.884		
≤ 1	104	68 (65.4)	36 (34.6)	1			
>1 – 3	276	163 (59.1)	113 (40.9)	0.76 (0.48-1.22)	0.261		
> 3	225	118 (52.4)	107 (47.6)	0.58 (0.36-0.94)	0.028*		
Received NNRTI-based ART during antepartum							
Not received NNRTI	586	352 (60.0)	248 (40.0)	1			
≤3 months	38	26 (68.4)	12 (31.6)	1.5 (0.7-3.1)	0.238		
>3 months	98	59 (60.2)	39 (39.8)	1.1 (0.7-1.6)	0.774		
Received PI-based ART during antepartum							
Not received PI	565	361 (63.9)	208 (36.1)	1			
≤3 months	54	29 (53.7)	25 (46.3)	0.6 (0.4-1.2)	0.160		
>3 months	113	47 (41.6)	66 (58.4)	0.4 (0.3-0.6)	<0.001*		
Maternal viral load within 4 weeks of delivery (copies/ml)							
<400	184	80 (43.5)	104 (56.5)	1			
≥400	77	43 (55.8)	34 (44.2)	1.64 (0.96-2.81)	0.069		
Gestational age at delivery (weeks);							
<37	77	48 (62.3)	29 (37.7)	1			
37-42	657	387 (58.9)	270 (41.1)	0.87 (0.53-1.40)	0.562		

**Table 2. Factors potentially correlated with seroreversion at 12 months of age
(continue)**

Variable	N	Seroreversion at 12 months of age		Crude OR (95%CI)	P	Adjusted OR (95%CI)	P**
		Seroreversion N (%)	No seroreversion N (%)				
Year of birth							
2000– 2006	322	219 (68.0)	103 (32.0)	1			
2007– 2009	176	116 (65.9)	60 (34.1)	0.91 (0.62-1.34)	0.633		
2010– 2014	238	102 (42.9)	136 (57.1)	0.35 (0.25-0.49)	<0.001*		
Year of birth according to the anti-HIV test kit used							
3 rd generation assay (2000-2012)	652	408 (62.6)	244 (37.4)	1			
4 th generation assay (2013-2014)	84	29 (34.5)	55 (65.5)	0.32 (0.19-0.51)	<0.001*	0.42(0.24-0.72)	0.002*

†AZT or d4T or TDF plus 3TC plus NVP or efavirenz

‡AZT or d4T or TDF plus 3TC plus boosted protease inhibitor

*P< 0.05 is significant

**Multivariable logistic regression model includes maternal age, maternal ART regimen antepartum, year of birth according to the anti-HIV test kit used

IQR indicates interquartile range; CI, confident interval; ART, antiretroviral therapy; AZT, zidovudine; d4T, stavudine; 3TC, lamivudine;

NNRTI, Non-nucleoside reverse transcriptase inhibitors; NVP, nevirapine; LPV/r, lopinavir/ritonavir; PI, protease inhibitor; OR, odds ratio.